Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 0693 • ACR Convergence 2022
Low Neutrophil Ectonucleotidase Activity Drives Neutrophil-Platelet Aggregation and Platelet Activation in Antiphospholipid Syndrome (APS)
Naveen Kumar S K¹, Claire Hoy¹, Srilakshmi Yalavarthi¹, Cyrus Sarosh², Kaitlyn Sabb¹, Christine Rysenga¹, Jacqueline Madison¹, Yu Zuo¹ and Jason S Knight³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI, ³University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: By converting extracellular ATP into homeostatic adenosine, the ectonucleotidases CD39 (ATP to AMP) and CD73 (AMP to adenosine) dictate extracellular purinergic gradients and as…
Abstract Number: 0678 • ACR Convergence 2022
Inpatient Epidemiology, Expenditures and Resource Utilization of Antiphospholipid Syndrome: National Inpatient Sample 2019
Patompong Ungprasert¹, Sunisa Kongkiatkamon², Ben Ponvilawan³, Nuttavut Sumransub⁴ and Paul Kroner⁵, ¹Cleveland Clinic, Cleveland Heights, OH, ²Chulalongkorn University, Bangkok, Thailand, ³Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, ⁴University of Minnesota, Minneapolis, MN, ⁵Mayo Clinic, Jacksonville, FL
Background/Purpose: Little is known about inpatient epidemiology, morbidity, mortality and resource utilization of patients with antiphospholipid syndrome (APS). The purpose of this study is to…
Abstract Number: 0694 • ACR Convergence 2022
Evaluation of the Effect of UCB4470 (anti-mouse FcRn) on Amelioration of Thrombosis in a Mouse Model of Antiphospholipid (aPL)-induced Thrombosis
Maria Laura Bertolaccini¹, Yiannis Ioannou², Helen Neale³, Prakash Saha¹ and Alberto Smith¹, ¹King's College London, London, United Kingdom, ²UCB Biopharma SRL, London, United Kingdom, ³UCB Biopharma SRL, Slough, United Kingdom
Background/Purpose: FcRn (the neonatal Fc receptor) is a receptor expressed by antigen-presenting cells, such as monocytes, macrophages, and dendritic cells, as well as on neutrophils.…
Abstract Number: 0679 • ACR Convergence 2022
Outcomes of Antiphospholipid Antibody Syndrome and Acute Coronary Syndrome: Analysis of National Inpatient Sample 
Faria Sami, Dennis Kumi and Shilpa Arora, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: Antiphospholipid antibody syndrome (APLS) is strongly associated with the risk of cardiovascular events including acute coronary syndrome (ACS). However, there is limited data on…
Abstract Number: 0943 • ACR Convergence 2022
Increased Prevalence of Thrombotic Events in Anti-Phospholipid Antibody-Positive SLE Patients on Estrogen-Containing Contraception
Hiba Bilal¹, Amarah Baluch² and Andras Perl³, ¹SUNY Upstate Medical Unviersity, Jamesville, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: Women of child-bearing age with underlying rheumatic disease such as systemic lupus erythematous (SLE) with positive anti-phospholipid antibodies (aPL) are at an increased risk…
Abstract Number: 0680 • ACR Convergence 2022
Association of Environmental Risk Factors with Antiphospholipid Antibodies and Thrombosis in 1199 International Patients Referred for Suspected Antiphospholipid Syndrome
Medha Barbhaiya¹, Deanna Jannat-Khah, DrPH, MSPH¹, Jonah Levine¹, Karen Costenbader² and Doruk Erkan¹, ¹Hospital for Special Surgery, New York, NY, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Whether environmental risk factors induce antiphospholipid antibody (aPL) positivity and increase the risk of arterial thrombosis (AT) and venous thromboembolism (VTE) in aPL-positive patients…
Abstract Number: 1066 • ACR Convergence 2022
Capillaroscopic Findings in Autoimmune Connective Tissue Diseases: Results from 20 Years of Experience in a Training Referral Center
Elvis Hysa, Carmen Pizzorni, Silvia Sammori, Emanuele Gotelli, Andrea Pogna, andrea cere, Carlotta Schenone, Veronica Gerli, sabrina Paolino, Alberto Sulli and Maurizio Cutolo, Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy
Background/Purpose: Nailfold videocapillaroscopy (NVC) allows the safe and fast detection of different microvascular patterns in patients affected by autoimmune connective tissue diseases (CTDs). The prevalence of…
Abstract Number: 0681 • ACR Convergence 2022
Antiphospholipid Antibodies and Incident Cardiovascular Events in a Diverse Population: Results from the Dallas Heart Study
Yu (Ray) Zuo¹, Sherwin Navaz¹, Wenying Liang¹, Chun Li², Colby Ayers³, Christine Rysenga¹, Alyssa Harbaugh¹, Gary Norman⁴, Elizabeth Solow³, Dami Akinmolayemi⁵, Anand Rohatgi³, David Karp⁶, Jason S Knight⁷ and James de Lemos³, ¹University of Michigan, Ann Arbor, MI, ²People's Hospital Peking University, Beijing, China, ³UT Southwestern Medical Center, Dallas, TX, ⁴Werfen, San Diego, ⁵Columbia University, New York, NY, ⁶UT Southwestern, Dallas, TX, ⁷University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: While circulating antiphospholipid antibodies (aPL) are recognized as an important acquired risk factor for thrombotic events, the prevalence of aPL in the general population…
Abstract Number: 1465 • ACR Convergence 2022
Clinical Profiling and Antiphospholipid Antibody (aPL) Associations in Indian Systemic Lupus Erythematosus (SLE) Cohort
Vineeta Shobha¹, Liza Rajasekhar², Sandra Manuel¹, Chengappa Kavadichanda³, Ashish J Mathew⁴, Ranjan Gupta⁵, Manish Rathi⁶, Parasar Ghosh⁷, Saumya Ranjan Tripathy⁸, Avinash Jain⁹ and Amita Aggarwal¹⁰, ¹St. John’s Medical College Hospital, Bangalore, India, ²Nizam's Institute of Medical Sciences, Madhapur, India, ³JIPMER, Pondicherry, Puducherry, India, ⁴Rigshospitalet, Copenhagen, Denmark, ⁵All India Institute of Medical Sciences, New Delhi, India, ⁶PGIMER Chandigarh, Chandigarh, India, ⁷Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁸SCB medical college, Cuttack, India, ⁹SMS Medical College, Lucknow, India, ¹⁰Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Antiphospholipid Antibody (aPL) are described in 11-40% of patients with SLE. Whether the presence of any of the aPLs or combinations thereof, can accurately…
Abstract Number: 0682 • ACR Convergence 2022
Analysis of Recurrent Thrombotic Events in a Large Single-center Primary Antiphospholipid Syndrome Cohort: Results from APS-Rio Cohort After over Than 600 Patients-year of Follow-up
Gustavo Balbi¹, Guilherme de Jesús² and Flavio Victor Signorelli², ¹Universidade de São Paulo, São Paulo, Brazil, ²Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil
Background/Purpose: To estimate the incidence rate of new thrombotic events in a large single-center prospective cohort of primary antiphospholipid syndrome (PAPS) patients after approximately 5.5…
Abstract Number: 1466 • ACR Convergence 2022
Cardiovascular Risk Assessment in Patients with Systemic Lupus Erythematosus: Comparison Between QRISK and aGAPSS Scores
Alice Barinotti¹, Massimo Radin¹, Irene Cecchi², Silvia Grazietta Foddai¹, Simone Baldovino¹, Elisa Menegatti¹, Daniela Rossi¹, Vittorio Modena¹, Dario Roccatello¹ and Savino Sciascia², ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy
Background/Purpose: Cardiovascular diseases (CVDs) represent one of the most life-threatening conditions that can affect SLE patients. Assessing the potential CVD risk of these patients is…
Abstract Number: 0683 • ACR Convergence 2022
ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases: Clinical and Serological Characteristics, Results from the APS ACTION Clinical Database and Repository
Irene Cecchi¹, Massimo Radin², Silvia Grazietta Foddai², Maria Laura Bertolaccini³, Danieli De Andrade⁴, Maria Tektonidou⁵, Vittorio Pengo⁶, Guillermo Ruiz-Irastorza⁷, H. Michael Belmont⁸, Maria Gerosa⁹, Paul Fortin¹⁰, Chary Lopez-Pedrera¹¹, Zhouli Zhang¹², Tatsuya Atsumi¹³, Guilherme de Jesus¹⁴, Hannah Cohen¹⁵, Nina Kello¹⁶, Ware Branch¹⁷, Denis Wahl¹⁸, Laura Andreoli¹⁹, Esther Rodriguez²⁰, Michelle Petri²¹, Megan R.W. Barber²², Ricard Cervera²³, Jason Knight²⁴, Bahar Artim-Esen²⁵, Rohan Willis²⁶, Guillermo Pons-Estel²⁷, Doruk Erkan²⁸ and Savino Sciascia¹, ¹University of Turin, Torino, Italy, ²University of Turin, Turin, Italy, ³King's College London, London, United Kingdom, ⁴University of São Paulo, São Paulo, Brazil, ⁵University of Athens, Athens, Greece, ⁶University of Padova, Padova, Italy, ⁷University of the Basque Country, Barakaldo, Spain, ⁸New York University School of Medicine, New York, NY, ⁹University of Milan, Milano, Italy, ¹⁰CHU de Québec Université Laval, Québec, QC, Canada, ¹¹Hospital Universitario Reina Sofía, Cordoba, Spain, ¹²Beijing Medical University, Beijing, China, ¹³Hokkaido University, Sapporo, Japan, ¹⁴Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁵University College London, London, United Kingdom, ¹⁶Northwell Health, New York, NY, ¹⁷University of Utah Health, Salt Lake City, ¹⁸Nancy University Hospital, Nancy, France, ¹⁹University of Brescia, Brescia, Italy, ²⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ²¹Johns Hopkins University School of Medicine, Baltimore, MD, ²²University of Calgary, Calgary, AB, Canada, ²³University of Barcelona, Barcelona, Spain, ²⁴University of Michigan, Ann Arbor, MI, ²⁵Istanbul University, Istanbul, Turkey, ²⁶University of Texas, Galveston, TX, ²⁷Centro Regional de Enfermedades Autoinmunes y Reumáticas, Rosario, Argentina, ²⁸Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: APS ACTION is an international Clinical Database and Repository of persistently antiphospholipid antibody (aPL)-positive subjects, collecting demographic, medical history, and aPL data.This study focused…
Abstract Number: 1677 • ACR Convergence 2022
Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells
Brian J. Mog¹, Elana R. Shaw¹, Michael S. Hwang¹, Alexander H. Pearlman¹, Sarah R. DiNapoli¹, Suman Paul¹, Chetan Bettegowda¹, Nickolas Papadopoulos¹, Sandra B. Gabelli¹, Michelle Petri², Antony Rosen¹, Shibin Zhou¹, Kenneth W. Kinzler¹, Bert Vogelstein¹ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the treatment of cancer and can be curative. CD19-targeted CAR-T cells hold promise for the treatment…
Abstract Number: 0684 • ACR Convergence 2022
Single Antiphospholipid Antibody Positive Thrombotic APS Patients’ Clinical Characteristics: Retrospective Results from the APS ACTION Clinical Database and Repository (Registry)
Silvia Grazietta Foddai¹, Irene Cecchi², Massimo Radin¹, Danieli De Andrade³, Maria Tektonidou⁴, Vittorio Pengo⁵, Guillermo Ruiz-Irastorza⁶, H. Michael Belmont⁷, Maria Gerosa⁸, Paul Fortin⁹, Rosario Lopez-Pedrera¹⁰, Zhouli Zhang¹¹, Tatsuya Atsumi¹², Guilherme de Jesus¹³, Hannah Cohen¹⁴, Nina Kello¹⁵, Ware Branch¹⁶, Denis Wahl¹⁷, Laura Andreoli¹⁸, Esther Rodriguez¹⁹, Michelle Petri²⁰, Ann E. Clarke²¹, Ricard Cervera²², Jason Knight²³, Bahar Artim-Esen²⁴, Rohan Willis²⁵, Guillermo Pons-Estel²⁶, Doruk Erkan²⁷, Dario Roccatello¹ and Savino Sciascia², ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy, ³University of São Paulo, São Paulo, Brazil, ⁴University of Athens, Athens, Greece, ⁵University of Padova, Padova, Italy, ⁶University of the Basque Country, Barakaldo, Spain, ⁷New York University School of Medicine, New York, NY, ⁸University of Milan, Milano, Italy, ⁹CHU de Québec Université Laval, Québec, QC, Canada, ¹⁰University of Cordoba, Cordoba, Spain, ¹¹Beijing Medical University, Beijing, China, ¹²Hokkaido University, Sapporo, Japan, ¹³Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁴University College London, London, United Kingdom, ¹⁵Northwell Health, New York, NY, ¹⁶University of Utah Health, Salt Lake City, ¹⁷Nancy University Hospital, Nancy, France, ¹⁸University of Brescia, Brescia, Italy, ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰Johns Hopkins University School of Medicine, Baltimore, MD, ²¹University of Calgary, Calgary, AB, Canada, ²²University of Barcelona, Barcelona, Spain, ²³University of Michigan, Ann Arbor, MI, ²⁴Istanbul University, Istanbul, Turkey, ²⁵University of Texas, Galveston, TX, ²⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas, Rosario, Argentina, ²⁷Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: The APS ACTION is a network collecting and analyzing data ofaPL positive patients recruited by international centers. Based on the assumption that triple aPL-positive…
Abstract Number: 1689 • ACR Convergence 2022
Oral Ginger Supplementation Counteracts NETosis in Autoimmune Mouse Models and in Healthy Humans
Ramadan Ali¹, Miela Zahavi², Christine Rysenga¹, Cyrus Sarosh³, Claire Hoy¹, Kristen Demoruelle⁴ and Jason S Knight⁵, ¹University of Michigan, Ann Arbor, MI, ²Universtiy of Michigan, Ann Arbor, MI, ³University of Michigan, Temperance, MI, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: It has previously been reported that 6-gingerol, the most abundant phytochemical in ginger root, inhibits neutrophil phosphodiesterase activity and thereby counteracts neutrophil hyperactivity in…

« Previous Page
1
…
5
6
7
8
9
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].